Activest Wealth Management
Position in XERS — Xeris Biopharma Holdings, Inc.
CIK 1883134
AVENTURA, FL
Position in XERS
as of Jun 30, 2026
· filed Jul 16, 2026
Position Value
$7,920
+$2,120 QoQ
Shares Held
1,000
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#211
of 238 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in XERS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Activest Wealth Management holds $149,357 across 17 Drug Manufacturers - Specialty & Generic names. XERS ranks #7 (5.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LQDA |
Liquidia Corp
|
486 | $38,748 | |
| 2 | ZTS |
Zoetis Inc.
|
387 | $27,809 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
44 | $23,840 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
2,000 | $20,000 | |
| 5 | NBIX |
Neurocrine Biosciences Inc
|
100 | $16,854 | |
| 6 | BHC |
Bausch Health Companies Inc.
|
1,900 | $9,367 | |
| 7 | XERS |
Xeris Biopharma Holdings, Inc.
This page
|
1,000 | $7,920 | |
| 8 | AKBA |
Akebia Therapeutics, Inc.
|
2,000 | $2,280 |
All Filings in XERS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,920 | 1,000 | Shares | Sole | 2026-07-16 | |
| 2026-03-31 | $5,800 | 1,000 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $7,850 | 1,000 | Shares | Sole | 2026-01-30 | |
| 2025-09-30 | $8,140 | 1,000 | Shares | Sole | 2025-11-03 | |
| 2025-06-30 | $4,670 | 1,000 | Shares | Sole | 2025-07-29 | |
| 2025-03-31 | $5,490 | 1,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $3,390 | 1,000 | Shares | Sole | 2025-01-28 | |
| 2024-09-30 | $2,850 | 1,000 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $2,250 | 1,000 | Shares | Sole | 2024-07-30 | |
| No filing history on record for this holder in this stock. | ||||||